Table 3.
Propensity score weight-adjusted odds ratios from logistic regression models, persistence and compliance (60-day gap allowance) with index therapy over 12 and 24 months
| Denosumab vs therapy | 12-month follow-up, OR (95% CI) | 24-month follow-up, OR (95% CI) | ||
|---|---|---|---|---|
| Persistence | Compliance | Persistence | Compliance | |
| Alendronate QD | 0.07 (0.05, 0.11) | 0.09 (0.06, 0.15) | 0.36 (0.22, 0.59) | 0.17 (0.10, 0.30) |
| Alendronate QW | 0.10 (0.09, 0.11) | 0.18 (0.16, 0.20) | 0.45 (0.40, 0.51) | 0.35 (0.31, 0.39) |
| Ibandronate QM | 0.10 (0.09, 0.11) | 0.18 (0.16, 0.21) | 0.44 (0.38, 0.50) | 0.34 (0.30, 0.39) |
| Ibandronate IV Q3M | 0.08 (0.05, 0.12) | 0.10 (0.06, 0.17) | 0.34 (0.20, 0.60) | 0.21 (0.11, 0.38) |
| Raloxifene QD | 0.12 (0.10, 0.14) | 0.22 (0.19, 0.26) | 0.64 (0.55, 0.74) | 0.47 (0.41, 0.55) |
| Risedronate QD | 0.12 (0.06, 0.26) | 0.15 (0.06, 0.35) | 0.39 (0.15, 1.03)* | 0.15 (0.05, 0.52) |
| Risedronate QW | 0.08 (0.07, 0.09) | 0.11 (0.09, 0.13) | 0.37 (0.32, 0.44) | 0.22 (0.18, 0.26) |
| Risedronate QM | 0.09 (0.07, 0.10) | 0.14 (0.12, 0.17) | 0.37 (0.31, 0.44) | 0.23 (0.19, 0.28) |
| Teriparatide SC QD | 0.25 (0.20, 0.30) | 0.46 (0.38, 0.57) | 0.95 (0.77, 1.16)† | 0.76 (0.62, 0.93) |
| Zoledronic acid IV annually | n/a | n/a | 0.76 (0.67, 0.86) | 0.76 (0.67, 0.86) |
Models adjusted for age, health plan type, US Census region, urban residency, patient out-of-pocket expenditure for the index therapy, and the following baseline clinical characteristics: Charlson Comorbidity Index score, number of unique medications prescribed, diagnosis of osteoporosis, osteopenia, renal insufficiency, gastrointestinal disorders, coronary heart disease, and osteoporosis-related fracture. CI confidence interval, IV intravenous, n/a not applicable, OR odds ratio, QD once daily, QM once monthly, Q3M once every 3 months, QW once a week, SC subcutaneous. P < 0.0001 for denosumab compared with all osteoporosis therapies
*P = 0.063; †P = 0.997